Bridges: A Digital Intervention to Increase Workplace Belonging

The purpose of this study is to evaluate Bridges, a digital program designed to support workplace belonging among LGBTQ+ employees. Belonging is an important part of health and well-being. People who feel accepted, valued, connected, and included often experience better mental and physical health. However, many LGBTQ+ individuals experience discrimination, stigma, exclusion, or isolation in workplace settings, which can negatively affect their sense of belonging and overall well-being. Bridges was developed to help LGBTQ+ employees build a stronger sense of belonging at work. The program combines personalized text messages with online activities, self-reflection exercises, practical workplace strategies, and opportunities to learn skills that may support connection, inclusion, and well-being. This study will enroll LGBTQ+ adults who are currently employed. Participants will use the Bridges program for approximately 30 days. During the study, participants will receive text messages and have access to online tools and activities. Participants will also complete surveys to assess their experiences, sense of workplace belonging, and feedback about the program. The primary purpose of this pilot study is to determine whether the Bridges program is feasible and acceptable to participants. Researchers will examine participant engagement with the program and satisfaction with its content and usability. The study will also explore whether participation in Bridges is associated with improvements in workplace belonging, well-being, and related outcomes. Information gathered from this study will be used to improve the program and guide future research on digital interventions designed to support belonging and well-being among LGBTQ+ employees.

NCT Number	NCT07634432
Lead Sponsor	Pro-Change Behavior Systems Collaborators: University of Pennsylvania
Conditions	Belonging, Mental Health, LGBTQ
Enrollment	136 participants
Start Date	2025-08-14
Primary Completion	2025-11-22 (estimated)
Study Completion	2025-11-22 (estimated)
Updated on ClinicalTrials.gov	2026-06-10